{
    "clinical_study": {
        "@rank": "144876", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing\n      so they stop growing or die. Thalidomide may stop the growth of cancer cells by stopping\n      blood flow to the cancer. Peripheral blood stem cell transplant using stem cells from the\n      patient or a donor may be able to replace immune cells that were destroyed by chemotherapy\n      used to kill cancer cells. The donated stem cells may also help destroy any remaining cancer\n      cells (graft-versus-tumor effect). It is not yet known whether chemotherapy followed by\n      peripheral blood stem cell transplant is more effective with or without thalidomide in\n      treating multiple myeloma.\n\n      PURPOSE: This randomized phase III trial is studying giving combination chemotherapy with\n      thalidomide to see how well it works compared with giving combination chemotherapy without\n      thalidomide in treating patients with multiple myeloma."
        }, 
        "brief_title": "Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma", 
        "condition": "Multiple Myeloma and Plasma Cell Neoplasm", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell", 
                "Plasmacytoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Compare the efficacy of doxorubicin, dexamethasone, and high-dose melphalan with versus\n           without thalidomide, in terms of event-free survival, of patients with multiple\n           myeloma.\n\n        -  Determine the response rate, complete response rate, overall survival, and\n           progression-free survival of patients treated with these regimens.\n\n        -  Determine the safety and toxicity of thalidomide in combination with intensive\n           chemotherapy in these patients.\n\n        -  Assess the value of prognostic factors at diagnosis in individual patients treated with\n           these regimens.\n\n      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to\n      participating center and treatment policy (1 course vs 2 courses of high-dose melphalan).\n      Patients are randomized to 1 of 2 treatment arms.\n\n      Arm I:\n\n        -  Patients receive induction chemotherapy (AD) comprising doxorubicin IV on days 1-4 and\n           oral dexamethasone on days 1-4, 9-12, and 17-20. Patients receive oral thalidomide\n           daily beginning on day 1 and continuing until 2 weeks before start of stem cell\n           mobilization. Treatment repeats every 28 days for 3 courses in the absence of disease\n           progression or unacceptable toxicity.\n\n        -  Patients receive stem cell mobilization with chemotherapy comprising cyclophosphamide\n           IV on day 1 and doxorubicin IV and oral dexamethasone on days 1-4 (CAD). Patients also\n           receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until\n           last apheresis.\n\n        -  Beginning 8-10 weeks after stem cell collection, patients receive low-dose oral\n           thalidomide daily and high-dose melphalan IV on days -3 and -2 as intensification.\n           Patients undergo stem cell infusion on day 0. Patients may receive a second course of\n           high-dose melphalan 2-3 months after the first course, in which case, stem cell\n           infusion follows the second course of melphalan.\n\n        -  Patients receive maintenance therapy with oral thalidomide daily until disease\n           progression or after 3 months if no response.\n\n        -  Beginning 2 months after the last course, patients with an HLA-identical sibling donor\n           undergo nonmyeloablative stem cell transplantation after radiotherapy.\n\n      Arm II:\n\n        -  Patients receive induction chemotherapy (VAD) comprising vincristine IV and doxorubicin\n           IV on days 1-4 and dexamethasone on days 1-4, 9-12, and 17-20. Treatment repeats every\n           28 days for 3 courses in the absence of disease progression or unacceptable toxicity.\n\n        -  Patients receive stem cell mobilization with CAD chemotherapy as in arm I. G-CSF is\n           given as in arm I.\n\n        -  Patients receive high-dose melphalan and undergo stem cell infusion as in arm I.\n\n        -  Patients receive maintenance therapy with interferon alfa SC 3 times weekly until\n           progression or after 3 months if no partial response.\n\n        -  Beginning 2 months after the last course, patients with an HLA-identical sibling donor\n           undergo nonmyeloablative stem cell transplantation after radiotherapy.\n\n      All patients are followed every 6 months for 3 years and then annually thereafter.\n\n      PROJECTED ACCRUAL: A total of 450 patients (225 per treatment arm) will be accrued for this\n      study within 4 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed multiple myeloma\n\n               -  Stage II or III\n\n          -  No systemic amyloid light-chain amyloidosis\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 to 65\n\n        Performance status:\n\n          -  WHO 0-3\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  No significant hepatic dysfunction*\n\n          -  Bilirubin less than 1.75 mg/dL*\n\n          -  AST/ALT less than 2.5 times normal* NOTE: *Unless related to myeloma\n\n        Renal:\n\n          -  Not specified\n\n        Cardiovascular:\n\n          -  No severe cardiac dysfunction\n\n          -  No New York Heart Association class II, III, or IV heart disease\n\n        Other:\n\n          -  HIV negative\n\n          -  No active uncontrolled infection\n\n          -  No other malignancy within the past 5 years except basal cell skin cancer or\n             carcinoma in situ of the cervix\n\n          -  No known intolerance to thalidomide\n\n          -  Not pregnant\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Patients 18 to 55 years of age must not have been allocated before study\n             randomization to allogeneic stem cell transplantation with an HLA-identical sibling\n             donor\n\n        Chemotherapy:\n\n          -  No more than 2 prior courses of melphalan and prednisone therapy for local myeloma\n             progression\n\n          -  No other prior chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Prior local radiotherapy for local myeloma progression allowed\n\n          -  No other prior radiotherapy\n\n        Surgery:\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 4, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00028886", 
            "org_study_id": "CDR0000069144", 
            "secondary_id": [
                "CKTO-2001-02", 
                "HOVON-50MM", 
                "EU-20133", 
                "HOVON-CKVO-2001-02"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "filgrastim", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "recombinant interferon alfa", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "dexamethasone", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "doxorubicin hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "melphalan", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "thalidomide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "vincristine sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "bone marrow ablation with stem cell support", 
                "intervention_type": "Procedure"
            }, 
            {
                "intervention_name": "peripheral blood stem cell transplantation", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Cyclophosphamide", 
                "Melphalan", 
                "Thalidomide", 
                "Lenograstim", 
                "Dexamethasone", 
                "Doxorubicin", 
                "Vincristine", 
                "Dexamethasone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "keyword": [
            "stage II multiple myeloma", 
            "stage III multiple myeloma"
        ], 
        "lastchanged_date": "September 16, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CKTO-2001-02"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "B-3000"
                    }, 
                    "name": "U.Z. Gasthuisberg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "'s-Gravenhage", 
                        "country": "Netherlands", 
                        "zip": "2545 CH"
                    }, 
                    "name": "HagaZiekenhuis - Locatie Leyenburg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "'s-Hertogenbosch", 
                        "country": "Netherlands", 
                        "zip": "5211 NL"
                    }, 
                    "name": "Jeroen Bosch Ziekenhuis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amersfoort", 
                        "country": "Netherlands", 
                        "zip": "3816 CP"
                    }, 
                    "name": "Meander Medisch Centrum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1066 CX"
                    }, 
                    "name": "Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1081HV"
                    }, 
                    "name": "Vrije Universiteit Medisch Centrum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1105 AZ"
                    }, 
                    "name": "Academisch Medisch Centrum at University of Amsterdam"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Enschede", 
                        "country": "Netherlands", 
                        "zip": "7500 KA"
                    }, 
                    "name": "Medisch Spectrum Twente"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands", 
                        "zip": "9713 EZ"
                    }, 
                    "name": "University Medical Center Groningen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leeuwarden", 
                        "country": "Netherlands", 
                        "zip": "8934 AD"
                    }, 
                    "name": "Medisch Centrum Leeuwarden - Zuid"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leiden", 
                        "country": "Netherlands", 
                        "zip": "2300 RC"
                    }, 
                    "name": "Leiden University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "6202 AZ"
                    }, 
                    "name": "Academisch Ziekenhuis Maastricht"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nieuwegein", 
                        "country": "Netherlands", 
                        "zip": "3435 CM"
                    }, 
                    "name": "Sint Antonius Ziekenhuis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nijmegen", 
                        "country": "Netherlands", 
                        "zip": "NL-6500 HB"
                    }, 
                    "name": "Universitair Medisch Centrum St. Radboud - Nijmegen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3008 AE"
                    }, 
                    "name": "Daniel Den Hoed Cancer Center at Erasmus Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584 CX"
                    }, 
                    "name": "University Medical Center Utrecht"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zwolle", 
                        "country": "Netherlands", 
                        "zip": "8000 GK"
                    }, 
                    "name": "Isala Klinieken - locatie Sophia"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Netherlands"
            ]
        }, 
        "official_title": "A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma", 
        "overall_official": {
            "affiliation": "UMC Utrecht", 
            "last_name": "H. Lokhorst, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "primary_outcome": {
            "measure": "Event-free survival", 
            "safety_issue": "No"
        }, 
        "reference": {
            "PMID": "18805967", 
            "citation": "Johnson DC, Corthals S, Ramos C, Hoering A, Cocks K, Dickens NJ, Haessler J, Goldschmidt H, Child JA, Bell SE, Jackson G, Baris D, Rajkumar SV, Davies FE, Durie BG, Crowley J, Sonneveld P, Van Ness B, Morgan GJ. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood. 2008 Sep 19; [Epub ahead of print]"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00028886"
        }, 
        "results_reference": [
            {
                "PMID": "22442350", 
                "citation": "Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Janssen JJ, Zijlmans M, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood. 2012 Jun 28;119(26):6219-25; quiz 6399. doi: 10.1182/blood-2011-11-393801. Epub 2012 Mar 22."
            }, 
            {
                "PMID": "19880501", 
                "citation": "Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010 Feb 11;115(6):1113-20. Epub 2009 Oct 30."
            }, 
            {
                "PMID": "18166796", 
                "citation": "Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreuz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Verhoef G, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H; Dutch-Belgian HOVON; German GMMG. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica. 2008 Jan;93(1):124-7."
            }, 
            {
                "citation": "Lokhorst H, van der Holt B, Zweegman S, et al.: Final analysis of HOVON-50 randomized phase III study on the effect of thalidomide combined with adriamycine,dexamethasone (AD) and high dose melphalan (HDM) in patients with multiple myeloma (MM). [Abstract] Blood 112 (11): A-157, 2008."
            }
        ], 
        "secondary_outcome": [
            {
                "measure": "Partial response and complete response", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Toxicity", 
                "safety_issue": "Yes"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Commissie Voor Klinisch Toegepast Onderzoek", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2001", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }, 
    "geocoordinates": {
        "Academisch Medisch Centrum at University of Amsterdam": "52.37 4.895", 
        "Academisch Ziekenhuis Maastricht": "50.851 5.691", 
        "Daniel Den Hoed Cancer Center at Erasmus Medical Center": "51.924 4.482", 
        "HagaZiekenhuis - Locatie Leyenburg": "52.07 4.301", 
        "Isala Klinieken - locatie Sophia": "52.499 6.084", 
        "Jeroen Bosch Ziekenhuis": "51.698 5.317", 
        "Leiden University Medical Center": "52.16 4.494", 
        "Meander Medisch Centrum": "52.156 5.388", 
        "Medisch Centrum Leeuwarden - Zuid": "53.201 5.8", 
        "Medisch Spectrum Twente": "52.222 6.894", 
        "Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital": "52.37 4.895", 
        "Sint Antonius Ziekenhuis": "52.03 5.082", 
        "U.Z. Gasthuisberg": "50.878 4.704", 
        "Universitair Medisch Centrum St. Radboud - Nijmegen": "51.843 5.855", 
        "University Medical Center Groningen": "53.219 6.567", 
        "University Medical Center Utrecht": "52.09 5.11", 
        "Vrije Universiteit Medisch Centrum": "52.37 4.895"
    }
}